首页|孟鲁司特钠联合氯雷他定治疗变应性鼻炎的临床效果观察

孟鲁司特钠联合氯雷他定治疗变应性鼻炎的临床效果观察

扫码查看
目的 探讨孟鲁司特钠联合氯雷他定治疗变应性鼻炎(AR)的临床效果.方法 选取 2021 年 1 月至 2022 年 12 月我院收治的 135 例AR患者,根据治疗方法的不同分为两组.对照组予以氯雷他定片治疗,研究组予以氯雷他定片联合孟鲁司特钠片治疗.比较两组的临床疗效、鼻腔生理功能以及不良反应.结果 研究组的治疗总有效率为 97.06%,显著高于对照组的 86.57%(P<0.05).治疗后,两组的MTT均显著短于治疗前,MCR、NR均显著低于治疗前(P<0.05);且研究组的MTT显著短于对照组,MCR、NR均显著低于对照组(P<0.05).两组治疗期间的不良反应总发生率比较,差异无统计学意义(P>0.05).结论 孟鲁司特钠联合氯雷他定治疗AR的效果确切,可明显改善患者的鼻腔功能,且安全性较高.
Observation on the Clinical Effect of Montelukast Sodium Combined with Loratadine in the Treatment of Allergic Rhinitis
Objective To explore the clinical effect of montelukast sodium combined with loratadine in the treatment of allergic rhinitis(AR).Methods 135 AR patients admitted to our hospital from January 2021 to December 2022 were selected and divided into two groups according to different treatment methods.The control group was treated with loratadine tablets,and the study group was treated with loratadine tablets combined with montelukast sodium tablets.The clinical efficacy,nasal physiological function and adverse reactions were compared between the two groups.Results The total effective rate of the study group was 97.06%,significantly higher than 86.57%of the control group(P<0.05).After treatment,the MTT of both groups was significantly shorter than that before treatment,and MCR and NR were significantly lower than those before treatment(P<0.05);The MTTs of the study group were significantly shorter than those of the control group,and MCR and NR were significantly lower than those of the control group(P<0.05).No significant difference was found in the total incidence of adverse reactions during treatment between the two groups(P>0.05).Conclusions Montelukast sodium combined with loratadine in the treatment of AR has exact effect,which can obviously improve patients'nasal function,and has high safety.

Montelukast sodiumLoratadineAllergic rhinitisClinical efficacyNasal functionAdverse reaction

周彩英、李海英

展开 >

郑州仁济医院耳鼻喉科,河南郑州 450000

孟鲁司特钠 氯雷他定 变应性鼻炎 临床疗效 鼻腔功能 不良反应

2024

临床医学工程
国家医疗保健器具工程技术研究中心

临床医学工程

影响因子:0.193
ISSN:1674-4659
年,卷(期):2024.31(2)
  • 9